Skip to main content
BELITE BIO, INC logo

BELITE BIO, INC — Investor Relations & Filings

Ticker · BLTE ISIN · US07782B1044 LEI · 984500BD54036BOEAE79 US Manufacturing
Open in API
Filings indexed 159 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country KY Cayman Islands
Listing US BLTE

About BELITE BIO, INC

https://belitebio.com/

Belite Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for retinal degenerative eye diseases and metabolic conditions with significant unmet medical needs. The company's lead candidate, Tinlarebant (LBS-008), is a novel oral therapy designed to reduce the accumulation of ocular toxins by targeting Retinol Binding Protein 4 (RBP4). Tinlarebant is in late-stage clinical development for the treatment of Stargardt disease (STGD1) and Geographic Atrophy (GA), an advanced form of dry age-related macular degeneration. The drug has received multiple regulatory designations, including Orphan Drug, Rare Pediatric Disease, Breakthrough Therapy, and Fast Track in the U.S., as well as Orphan Drug designation in Europe and Sakigake designation in Japan.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 87% confidence The document is a short Form 6-K filing (Report of Foreign Private Issuer) that attaches a press release as Exhibit 99.1. It does not include substantive financial statements itself but merely furnishes a regulatory report and refers to an external press release. Per the “menu vs meal” rule and because Form 6-K is a miscellaneous SEC filing category, this falls under Regulatory Filings (RNS).
2026-05-20 English
6-K - BELITE BIO, INC (0001889109) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Belite Bio, Inc, with the SEC. It contains a press release about the initiation of a rolling submission of a New Drug Application to the FDA. The document is short (2062 characters) and primarily serves to furnish information via a press release. It does not contain detailed financial statements, management discussion, or comprehensive report data. According to the rules, such filings that provide a press release or announcement without substantive financial data or detailed report content should be classified as Regulatory Filings (RNS).
2026-04-21 English
6-K - BELITE BIO, INC (0001889109) (Filer)
Report Publication Announcement Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Belite Bio, Inc, pursuant to SEC rules. It references a press release announcing the availability of the Annual Report on Form 20-F through the company website, but does not contain the report itself or substantive financial data. The document length is short (1932 characters) and primarily serves as an announcement of the report's availability. According to the 'Menu vs Meal' rule, this is a report publication announcement rather than the report itself. Therefore, the appropriate classification is Report Publication Announcement (RPA).
2026-03-31 English
20-F - BELITE BIO, INC (0001889109) (Filer)
Annual Report FY 2025
2026-03-31 English
3 - BELITE BIO, INC (0001889109) (Issuer)
Director's Dealing
2026-03-18 English
3 - BELITE BIO, INC (0001889109) (Issuer)
Director's Dealing
2026-03-18 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.